SenesTech Q3 2024 revenue up 51% YTD; gross margin 65% record; operating expenses down 12%

SenesTech, Inc.

2024-Q3 EPS reported -$8.40 revenue$1,356,000

YTD revenue $1.4M, +51% YoY; Q3 gross margin 65% vs 49% in prior year.
Operating expenses down 12% in Q3; adjusted EBITDA loss narrowed 21% vs prior year.
New products Evolve Rat and Evolve Mouse contributed 52% and 17% of Q3 revenue respectively.
NYC rat contraception pilot bill approved; SenesTech only EPA-registered manufacturer; supply proposal under negotiation.
International expansion: HK registration, Netherlands multi-pallet order, exclusive distributor selection in India, Pakistan, Chile, Brazil, Taiwan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.